Insights - Aldeyra (ALDX) will be reporting results from their first Phase 3 study in allergic conjunctivitis (“AC”) sometime in early 2019 (we expect January). A positive … Continue Reading
Read NowInsights - Today Fennec (FENC) announced that the company initiated its rolling NDA for chemo induced hearing loss in patients 1 month- 18 years of age with localized, solid … Continue Reading
Read NowInsights - Yesterday after market, Achillion (ACHN) released data and a strategic update, including interim data for C3G and PNH indications. The stock was down 20% leading up to … Continue Reading
Read NowInsights - During their R&D Day call last week, Affimed shared details on the clinical development plan for AFM13 in lymphomas. These future plans were a positive development after … Continue Reading
Read NowInsights - Bellus announced a $35M CDN raise this morning at $0.95 CDN. That is roughly equivalent to $0.71 USD. The Company is expected to net around $33M CDN, … Continue Reading
Read NowInsights - Oncosec finally announced an update from their early stage triple negative breast cancer trial. This data was presented last Thursday at the San Antonio Breast Conference. For … Continue Reading
Read NowInsights - There is a misconception that Bellus is lacking catalysts following their strong Phase 1 data released last week (read here). We don’t necessarily agree with the … Continue Reading
Read Now
